Viking Therapeutics, Inc. (VKTX) Q4 2022 Earnings Results

Viking Therapeutics Misses on EPS, Stock Down 4.02%

Viking Therapeutics reported a loss that was slightly worse than expected, resulting in a 4.02% decline in stock price. The lack of revenue information and absence of guidance may have contributed to investor uncertainty. The company's focus on clinical trials suggests they are prioritizing long-term growth despite short-term losses.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.26	N/A	-11.59%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management remains focused on advancing their clinical programs. They highlighted the significance of future data but did not offer specific guidance.

Management noted ongoing efforts in clinical trials and development.

They emphasized the importance of upcoming data releases.

No specific guidance was provided for future performance.

Viking Therapeutics Misses on EPS, Stock Down 4.02%

Key numbers

Management commentary

Viking Therapeutics, Inc.

More earnings this week

Viking Therapeutics Misses on EPS, Stock Down 4.02%

Key numbers

Management commentary